Carlos le Sage, Ph.D., is manager of the Functional Genomic Screening Platform at Horizon Discovery. Le Sage’s research focuses on discovering the mechanism of action of newly developed compounds and defining new synthetic lethal interactions in defined mutant-driven cancer genomes, through unbiased genetic perturbation screens. Le Sage has many years of experience in the development and use of functional genomic techniques, initially with RNAi and more recently with CRISPR gene modifying and modulating technologies for genome-wide loss- and gain-of-function screening.
Since joining Horizon Discovery, le Sage has engaged in a large number of client-based projects centred on functional genomics. He received the Trailblazer Award for his involvement in developing and providing CRISPR activation and interference genome-wide screen technologies as off-the-shelf services in 2017. Prior to joining Horizon Discovery, le Sage completed postdoctoral research with Prof. Steve Jackson at the Gurdon Institute in Cambridge. He holds a Ph.D. in biology from the Netherlands Cancer Institute through Leiden University.
SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members. > READ MORE
February 21, 2020